Microencapsulated drug delivery: A new approach to pro-inflammatory cytokine inhibition

Journal of Microencapsulation

Volumn 29, Issue 5, 2012, Pages 455-462

  Oettinger, Carl W ^a   D'Souza, Martin J ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

antioxidant catalase; antisense oligonucleotides; endothelium; NF kappaB; phagocytosis; sepsis; TNF

Indexed keywords

ALBUMIN MICROSPHERE; ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CATALASE; CLODRONIC ACID; DEXAMETHASONE; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; NEUTRALIZING ANTIBODY; SEMAPIMOD; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ADJUVANT ARTHRITIS; BACTERIAL PERITONITIS; CELL MEMBRANE PERMEABILITY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG UPTAKE; ENDOTHELIUM CELL; MACROPHAGE; MICROCAPSULE; MICROEMULSION; MICROENCAPSULATION; NONHUMAN; PERITONITIS; PHAGOCYTE; PHAGOCYTOSIS; REVIEW; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ALBUMINS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIOXIDANTS; CAPSULES; CATALASE; CYTOKINES; DRUG COMPOUNDING; GLUCOCORTICOIDS; HUMANS; HYDRAZONES; IMMUNOSUPPRESSIVE AGENTS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 84863800625     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.658443     Document Type: Review

References (40)

1. Akhavein N, Oettinger C, Gayakawad S, Addo R, Bejugam N, Bauer J, Pollock S, D'Souza M. Treatment of adjuvant arthritis using microencapsulated antisense to NF-B oligonucleotides. J Microencapsulation, 2008;18:1-12.
2. Andreakos ET, Feldman M. 2003. Autoimmunity and cytokines: Pathogenesis and therapy. In: Thomsom AW, Lotze MT, eds. The cytokine handbook. 4th ed. Vol. II. San Diego, CA: Academic Press, pp. 1189-211.
3. Bagby G, Plessala K, Wilson L, Thompson J, Nelson S. Divergent efficacy of antibody to tumor necrosis factor- in intravascular and peritonitis models of sepsis. J Infect Dis, 1991;163:83-8.
4. Bender A, Schafer V, Steffan AM, Royer C, Kreuter J, Rubsamen- Waigmann H, von Briesen H. Inhibition of HIV in-vitro by antiviral drug-targeting using nanoparticles. Res Virol, 1994;145:215-20.
5. Bianchi M, Bloom O, Raabe T, Cohen PS, Chesney J, Sherry B, Schmidtmayerova H, Calandra T, Zhang X, Bukrinsky M. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med, 1996;183:927-36.
6. Bianchi M, Ulrich P, Bloom O, Meistral III M, Zimmerman GA, Schmidtmayerova H, Bukrinsky M, Donnelley T, Bucala R, Sherry B. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol Med, 1995;1:254-66.
7. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med, 2001;344:907-15.
8. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G. Glucocorticoid mediated repression of nuclear factor-B dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA, 1997;94:13504-9.
9. De Oliveira-Marques V, Cyrne L, Marinho HS, Antunes F. A quantitative study of NF-B activation by H2O2: Relevance in inflammation and synergy with TNF-. J Immunol, 2007;178:3893-902.
10. Dinarello CA. 2010. Introduction: Cytokine biology relevant to infectious diseases. Cytokines and chemokines. In: Kotb M, Calandra T, eds. Cytokines and chemokines in infectious diseases handbook. 2nd ed. Totowa, NJ: Humana Press, pp. 1-92.
11. Doi K, Leelahavanichkul A, Yuen PSTG, Star RA. Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest, 2009;119:2868-78.
12. D'Souza MJ, DeSouza P. Site specific microencapsulated drug targeting strategies-liver and gastro-intestinal tract targeting. Adv Drug Delivery Rev, 1995;17:247-54.
13. D'Souza M, Jin Z, Oettinger C. Treatment of experimental septic shock with microencapsulated antisense oligomers to NF-B. J Interferon Cytokine Res, 2005;25:311-20.
14. D'Souza MJ, Oettinger CW, Milton GW. Microspheres containing neutralizing antibodies to tumor necrosis factor- and interleukin-1- protect rats form Staphloccus aureus-induced peritonitis. J Interferon Cytokine Res, 2000;20:907-13.
15. D'Souza M, Oettinger C, Milton G, Tracey K. Prevention of lethality and suppression of proinflammatory cytokines in experimental septic shock by microencapsulated CNI-1493. J Interferon Cytokine Res, 1999;19:1125-33.
16. D'Souza MJ, Oettinger CW, Shah A, Tipping PG, Huang XR, Milton GV. Macrophage depletion by albumin microencapsulated clodronate: Attenuation of cytokine release in macrophage-dependent lomerulonephritis. Drug Dev Ind Pharm, 1999;25:591-6.
17. Gayakwad SG, Bejugam NK, Akhavein N, Uddin NA, Oettinger CW, D'Souza MJ. Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-B encapsulated microspheres. J Microencapsulation, 2009;26:692-700.
18. Iles KE, Forman HJ. Macrophage signaling and respiratory burst. Immun Res, 2002;26:95-105.
19. Leonard EJ, Yoshimura T. Human Monocyte chemoattractant Protein- 1(MCP-1). Immunol Today, 1990;11:97-101.
20. Ma A, Qi S, Chen H. Antioxidant therapy for prevention of inflammation, ischemic reperfusion injuries and allograft rejection. Cardiovasc Hematol Agents Med Chem, 2008;6:20-43.
21. Michie HR, Mangonogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med, 1988;318:1481-6.
22. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein. N Engl J Med, 1997;337:141-7.
23. Oettinger CW, D'Souza MJ. Microencapsulation of tumor necrosis factor oligomers: A new approach to pro-inflammatory cytokine inhibition. J Interferon Cytokine Res, 2003;23:533-43.
24. Oettinger CW, D'Souza MJ. Synergism in survival to endotoxic shock in rats given microencapsulated CNI-1493 and antisense oligomers to NF-B. J Microencapsulation, 2010;27:372-6.
25. Oettinger CW, D'Souza M, Akhavein N, Peer G, Taylor F, Kinsaewitz G. Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-B. J Microencapsulation, 2007;24: 337-48.
26. Oettinger CW, D'Souza M, Milton G. Targeting macrophages with microspheres containing cytokine-neutralizing antibodies prevents lethality in gram-negative peritonitis. J Interferon Cytokine Res, 1999; 19:33-40.
27. Okusawa AS, Gelfand J, Ikejima T. Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest, 1988;81:1162-72.
28. Oliver JC, Bland LA, Oettinger CW, Arduino MJ, McAllister SK, Aguero SM, Favero M.S. Cytokine kinectics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res, 1993;12:115-20.
29. Pantano C, Reynaert NL, van der Vliet A, Janssen-Heninger YM. Redoxsensitive kinases of the nuclear factor-B signaling pathway. Antioxid Redox Signal, 2006;8:1791-806.
30. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transrepression of NF-B by activated glucocorticoid receptors. Mol Cell Biol, 1995;15:943-53.
31. Shafer V, Briesen HV, Rubsamen-Waigmann H, Steffan AM, Royer C, Kreuter J. Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages. J Microencapsulation, 1994;11:261-9.
32. Siwale RC, Oettinger CW, Addo R, Yeboah GK, D'Souza MJ. The effect of intracellular antioxidant delivery (catalase) on hydrogen peroxide and proinflammatory cytokine synthesis: A new therapeutic horizon. J Drug Target, 2009;17:710-18.
33. Siwale RC, Oettinger CW, Pai SB, Addo R, Uddin N, Siddig A, D'Souza MJ. Formulation and characterization of catalase in albumin microspheres. J Microencapsulation, 2008;26(5):411-19.
34. Smith-Oliver T, Noel L, Stimson S, Yarnall D, Connolly K. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine, 1993;5:298-304.
35. Szekanecz Z, Halloran M, Volin M, Woods J, Streiter R, Haines K, Kunkel S, Burdick M, Koch A. Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum, 2000; 43:1266-77.
36. Uddin MN, Siddig A, Oettinger CW, D'Souza MJ. Potentiation of proinflammatory cytokine suppression and survival by microencapsulated dexamethasone in the treatment of experimental sepsis. J Drug Target, 2011;19(9):752-60.
37. Van Rooijen N, Kors N, Vander Ende M, Dikstra CD. Depletion and repopulation of macrophages in spleen and liver of the rat after intravenous treatment with liposome-encapsulated dichloromethelyne diphosphate. Cell Tissue Res, 1990;260:215-22.
38. Ward JH, Cloud RS. Comparative effect of anti-rheumatic drugs on adjuvant-induced polyarthritis in rats. J Pharm Exp Ther, 1966;152: 116-21.
39. Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol, 2011;22:999-1006.
40. Zhaowei J, D'Souza MJ, Oettinger CW. Reversal of LPS induced endothelial cell TNF synthesis and increased permeability with microencapsulated antisense oligomers to NF-B. J Microencapsulation, 2007;24: 596-607.